We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Potential Kidney Disease Treatment Discovered in Mouse Study

Many blister packs containing different medications.
Credit: freestocks.org/ Pexels
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

In a study in mice scientists found that medicines usually used to treat angina and high blood pressure prevented much of the long-term damage to the kidney and cardiovascular system caused by acute kidney injury (AKI).

Experts hope the findings will pave the way for improved treatment of AKI – a common illness that occurs in approximately 20 per cent of emergency hospital admissions in the UK.

The condition is usually caused by other illnesses that reduce blood flow to the kidney, or due to toxicity arising from some medicines.

Kidney damage

AKI must be treated quickly to prevent death. Even if the kidneys recover, AKI can cause long lasting damage to the kidneys and the cardiovascular system.

Of those who survive an episode of AKI, 30 per cent are left with chronic kidney disease (CKD). The remaining 70 per cent that recover full kidney function are at an almost 30-fold increased risk of developing CKD.

A team from the University of Edinburgh found that patients with AKI had increased blood levels of endothelin – a protein that activates inflammation and causes blood vessels to constrict. Endothelin levels remained high long after kidney function had recovered.

Mouse study

After finding the same increase in endothelin in mice with AKI, experts treated the animals with medicines that block the endothelin system. The medicines – normally used to treat angina and high blood pressure – work by stopping the production of endothelin or by shutting off endothelin receptors in cells.

The mice were monitored over a four-week period after AKI. Those that were treated with the endothelin-blocking medicines had lower blood pressure, less inflammation and reduced scarring in the kidney.

Their blood vessels were more relaxed and kidney function was also improved, compared with untreated mice.

The study is published in Science Translational Medicine. It was funded by the Medical Research Council and the British Heart Foundation.

AKI is a harmful condition, particularly in older people and even with recovery it can have a long-term impact on a person’s health. Our study shows that blocking the endothelin system prevents the long-term damage of AKI in mice. As these medicines are already available for use in humans, I hope that we can move quickly to seeing if the same beneficial effects are seen in our patients.

Dr Bean DhaunSenior Clinical Lecturer and Honorary Consultant Nephrologist at the University of Edinburgh’s Centre for Cardiovascular Science

Impaired kidney function that results from acute kidney injury can also increase a person’s chance of developing and dying from heart and circulatory diseases, so it’s vital we find ways to reduce this risk. This promising research suggests that widely available medicines could help to tackle the impact of acute kidney injury before it can cause damage and further complications. While further studies will be needed to demonstrate whether this treatment is safe and effective for patients, this early research is an encouraging first step.

Professor James LeiperAssociate Medical Director at the British Heart Foundation

Reference: Czopek A, Moorhouse R, Gallacher PJ, et al. Endothelin blockade prevents the long-term cardiovascular and renal sequelae of acute kidney injury in mice. Sci Transl Med. 2022;14(675):eabf5074. doi: 10.1126/scitranslmed.abf5074

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.